| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Africa reaffirms commitments to eliminate cervical cancer
|
Makoni, Munyaradzi
|
|
|
24 |
10 |
p. 1065
|
article
|
| 2 |
Amelanotic melanoma presented as multiple flesh-coloured islands
|
Chen, Tai-Li
|
|
|
24 |
10 |
p. e424
|
article
|
| 3 |
Cancer advocates call for national cancer body in South Africa
|
Makoni, Munyaradzi
|
|
|
24 |
10 |
p. 1066
|
article
|
| 4 |
Cancer care after the wildfires in Hawai'i
|
Das, Manjulika
|
|
|
24 |
10 |
p. 1064
|
article
|
| 5 |
Cancer care in Sri Lanka amid financial crisis
|
Das, Manjulika
|
|
|
24 |
10 |
p. e406
|
article
|
| 6 |
Cancer germline predisposing variants and late mortality from subsequent malignant neoplasms among long-term childhood cancer survivors: a report from the St Jude Lifetime Cohort and the Childhood Cancer Survivor Study
|
Chen, Cheng
|
|
|
24 |
10 |
p. 1147-1156
|
article
|
| 7 |
Cancer-predisposing germline variants and subsequent cancer risk
|
Ronckers, Cécile M
|
|
|
24 |
10 |
p. 1059-1061
|
article
|
| 8 |
Combination immunotherapy in chemotherapy in gastric cancer
|
Shiraishi, Kazuhiro
|
|
|
24 |
10 |
p. 1054-1055
|
article
|
| 9 |
Combination therapies in non-clear-cell renal cell carcinoma
|
Aslan, Volkan
|
|
|
24 |
10 |
p. e401
|
article
|
| 10 |
Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer
|
Martini, Alberto
|
|
|
24 |
10 |
p. 1056-1057
|
article
|
| 11 |
Common Sense Oncology: including everyone
|
Ergun, Yakup
|
|
|
24 |
10 |
p. e403
|
article
|
| 12 |
Common Sense Oncology: including everyone
|
André, Nicolas
|
|
|
24 |
10 |
p. e402
|
article
|
| 13 |
Common Sense Oncology: including everyone – Authors' reply
|
Booth, Christopher M
|
|
|
24 |
10 |
p. e404
|
article
|
| 14 |
Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial
|
Mutter, Robert W
|
|
|
24 |
10 |
p. 1083-1093
|
article
|
| 15 |
Correction to Lancet Oncol 2023; 24: 1042–52
|
|
|
|
24 |
10 |
p. e405
|
article
|
| 16 |
Correction to Lancet Oncol 2023; 24: 989–1001
|
|
|
|
24 |
10 |
p. e405
|
article
|
| 17 |
Correction to Lancet Oncol 2023; 24: 892–902
|
|
|
|
24 |
10 |
p. e405
|
article
|
| 18 |
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial
|
Aronson, S Lot
|
|
|
24 |
10 |
p. 1109-1118
|
article
|
| 19 |
Defining an evidence-based strategy for streamlining cancer multidisciplinary team meetings
|
Soukup, Tayana
|
|
|
24 |
10 |
p. 1061-1063
|
article
|
| 20 |
Developing cancer rehabilitation services and research in low-income and middle-income countries: the case for Zambia and key messages
|
Davie, Mulenga
|
|
|
24 |
10 |
p. 1069-1071
|
article
|
| 21 |
Dysphagia-optimised intensity-modulated radiotherapy versus standard radiotherapy in patients with pharyngeal cancer
|
Das, Biswajyoti
|
|
|
24 |
10 |
p. e397
|
article
|
| 22 |
Dysphagia-optimised intensity-modulated radiotherapy versus standard radiotherapy in patients with pharyngeal cancer
|
McDowell, Lachlan
|
|
|
24 |
10 |
p. e396
|
article
|
| 23 |
Dysphagia-optimised intensity-modulated radiotherapy versus standard radiotherapy in patients with pharyngeal cancer – Authors' reply
|
Nutting, Christopher
|
|
|
24 |
10 |
p. e398
|
article
|
| 24 |
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial
|
Cytryn, Samuel L
|
|
|
24 |
10 |
p. 1073-1082
|
article
|
| 25 |
Global oncology research and training at US National Cancer Institute-designated cancer centres: results of the 2021 Global Oncology Survey
|
Garton, Elise M
|
|
|
24 |
10 |
p. e407-e414
|
article
|
| 26 |
Hyperthermic intraperitoneal chemotherapy for ovarian cancer: long-term findings from the OVHIPEC-1 trial
|
Ghirardi, Valentina
|
|
|
24 |
10 |
p. 1057-1059
|
article
|
| 27 |
Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement
|
Cui, Wanda
|
|
|
24 |
10 |
p. e415-e423
|
article
|
| 28 |
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
|
Saad, Fred
|
|
|
24 |
10 |
p. 1094-1108
|
article
|
| 29 |
Patient first; person first
|
The Lancet Oncology,
|
|
|
24 |
10 |
p. 1053
|
article
|
| 30 |
Pembrolizumab monotherapy for advanced chordoma
|
Hu, Xianglin
|
|
|
24 |
10 |
p. e399
|
article
|
| 31 |
Pembrolizumab monotherapy for advanced chordoma – Authors' reply
|
Blay, Jean-Yves
|
|
|
24 |
10 |
p. e400
|
article
|
| 32 |
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
|
Gao, Xiangyu
|
|
|
24 |
10 |
p. 1134-1146
|
article
|
| 33 |
The deaf doctor
|
Wein, Simon
|
|
|
24 |
10 |
p. 1072
|
article
|
| 34 |
The UK rejoins Horizon Europe
|
Burki, Talha Khan
|
|
|
24 |
10 |
p. 1067
|
article
|
| 35 |
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study
|
van de Donk, Niels W C J
|
|
|
24 |
10 |
p. 1119-1133
|
article
|
| 36 |
US Government convenes first National Cancer Plan stakeholders' meeting
|
Furlow, Bryant
|
|
|
24 |
10 |
p. 1068
|
article
|
Journal description